.Pharmacolibrary.Drugs.ATC.M.M03AC11 .Pharmacolibrary.Drugs.ATC.M.M03AC11| name: | Cisatracurium |
| ATC code: | M03AC11 | route: | intravenous |
| n-compartments | 2 |
Cisatracurium is a non-depolarizing neuromuscular blocking agent used for skeletal muscle relaxation during surgical procedures and mechanical ventilation in intensive care units. It is a benzylisoquinolinium compound and is approved for clinical use today, particularly favored due to organ-independent metabolism (Hofmann elimination), making it suitable for patients with hepatic or renal impairment.
Typical pharmacokinetics in healthy adult patients after single intravenous bolus dose; parameters largely independent of age and sex due to predominant Hoffman elimination.
Kisor, DF, & Schmith, VD (1999). Clinical pharmacokinetics of cisatracurium besilate. Clinical pharmacokinetics 36(1) 27–40. DOI:10.2165/00003088-199936010-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9989341
Dahaba, AA, et al., & Reibnegger, G (2022). Location matters: Overlooked ethnic-geographic effect in China and Austria on propofol/cisatracurium sex differences among a population pharmacokinetic/pharmacodynamic (PopPK/PD) covariate analysis in men, women, and one transgender subject. Fundamental & clinical pharmacology 36(1) 182–198. DOI:10.1111/fcp.12704 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34050969
Muravchick, S (1998). The effects of aging on anesthetic pharmacology. Acta anaesthesiologica Belgica 49(2) 79–84. PUBMED:https://pubmed.ncbi.nlm.nih.gov/9675376